ubivac Press Releases

Published on November 18, 2025 - 07:21 GMT

UbiVac CEO Presents Pioneering Dark-Matter Cancer Vaccine Advances at Parker Institute for Cancer Immunotherapy Workshop

Clinical Data Show DPV-001 Combo immunotherapy Triples Response Rates, PFS, and Doubles Overall Survival Over Standard of Care NEW YORK, NY, UNITED STATES, November 17, 2025 /⁨EINPresswire.com⁩/ -- UbiVac, www.ubivac.com, a private, clinical-stage Immuno- …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on November 11, 2025 - 05:29 GMT

UbiVac Showcases First 'Dark Matter' Cancer Immunotherapy Data at SITC 2025

DPV-001, first cancer vaccine derived from the human dark genome, shows improved survival in head and neck cancer and reveals more than 400 new antigen targets. NATIONAL HARBOR, MD, UNITED STATES, November 10, 2025 /⁨EINPresswire.com⁩/ -- UbiVac, https:// …

Distribution channels: Banking, Finance & Investment Industry, Education ...

Published on May 8, 2025 - 10:00 GMT

UbiVac CEO Participates in Cancer Vaccine Panel at SynBioBeta & Wilson Sonsini Investment Forum

AI will accelerate discovery, but the breakthrough is off‑the‑shelf vaccines targeting shared Dark‑Genome drivers—paired with nextgen immunotherapy combinations PALO ALTO AND SAN JOSE, CA, UNITED STATES, May 8, 2025 /⁨EINPresswire.com⁩/ -- At SynBioBeta, …

Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...

Published on May 5, 2025 - 13:30 GMT

UbiVac Presents 1st Report of In Vivo Generated T Cell Receptor (TCR) to Dark Genome-Derived Cancer’s Dark Matter

UbiVac’s DPV-001 induces Development of 1st in-patient generated TCR to Non-Small Cell Lung Cancer’s “Dark Matter” – Targets cancer without apparent toxicity HONOLULU, HI, UNITED STATES, May 5, 2025 /⁨EINPresswire.com⁩/ -- UbiVac, www.ubivac.com, a …

Distribution channels: Banking, Finance & Investment Industry, Chemical Industry ...

Published on March 19, 2025 - 08:32 GMT

UbiVac to present on Dark Genome-derived Dark Matter/Proteome Cancer Immunotherapy at Spring 2025 Venture Forum

UbiVac's DPV-001 is the World's 1st Dark Matter Cancer Immunotherapy in the Clinic - Promising Early Data Supports Phase II Trial PORTLAND, OR, UNITED STATES, March 19, 2025 /⁨EINPresswire.com⁩/ -- UbiVac, www.ubivac.com, a private, clinical-stage …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on November 8, 2024 - 00:00 GMT

Promising Phase Ib Data for UbiVac’s DPV-001 in Combination Immunotherapy for Head and Neck Squamous Cell Cancer

UbiVac's DPV-001 Dark Matter combo Immunotherapy triples response rate and progression-free survival over PD-1 alone for patients with r/m head and neck cancer HOUSTON, TX, UNITED STATES, November 7, 2024 /⁨EINPresswire.com⁩/ -- UbiVac, www.ubivac.com …

Distribution channels: Banking, Finance & Investment Industry, Companies ...

Published on April 6, 2024 - 17:19 GMT

DPV-001 Vaccine Containing Cancer’s “Dark Matter” Yields 2 to >3-fold Increased Response Rate for Head and Neck Cancer

Positive Data from Phase Ib Study Evaluating UbiVac’s DPV-001 as Combination Immunotherapy for Head and Neck Squamous Cell Cancer Presented at AACR Meeting PORTLAND, OR, USA, April 6, 2024 /⁨EINPresswire.com⁩/ -- • UbiVac Announces a 2 to >3-fold …

Distribution channels: Banking, Finance & Investment Industry, Education ...

Published on April 8, 2022 - 16:15 GMT

UbiVac Announces Preliminary Immunological Data from 1st-In-Human Trial of DPV-001 Immunotherapy Trio for Advanced HNSCC

Data from Clinical Trial of DPV-001 & Anti-PD-1 +/- anti-GITR for Head & Neck Squamous Cell Cancer (HNSCC) Presented at American Association for Cancer Research NEW ORLEANS, LOUISIANA, USA, April 8, 2022 /⁨EINPresswire.com⁩/ -- UbiVac, www.ubivac. …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on October 29, 2020 - 12:30 GMT

FDA Grants Approval for UbiVac Manufactured Coronavirus Vaccine to Start Clinical Trial

Providence St. Joseph Health, one of the national’s leading non-profit health systems, and the Providence Cancer Institute to run Phase 1 clinical trial PORTLAND, OREGON, UNITED STATES, October 29, 2020 /⁨EINPresswire.com⁩/ -- UbiVac Inc., a clinical …

Distribution channels: Banking, Finance & Investment Industry, Chemical Industry ...

Published on October 17, 2020 - 22:18 GMT

Dr Bernard Fox joins CCFDIE Immunotherapy Workshop to Talk UbiVac’s Combination Immunotherapy for Advanced Breast Cancer

China Center for Food and Drug International Exchange hosts International Immunotherapy Experts to Discuss State-of-Art and Future Treatments for Cancer BEIJING, CHINA, October 17, 2020 /⁨EINPresswire.com⁩/ -- UbiVac Inc’s co-founder and CEO, Bernard A. …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on October 16, 2020 - 06:22 GMT

Immuno-Oncology Pioneer Dr. Jon M. Wigginton Joins UbiVac’s Board of Directors

Dr. Jon Wigginton, internationally recognized developer of immunotherapies, advisor to MPM Capital and CMO at Cullinan Oncology, to join UbiVac's Board PORTLAND, OREGON, UNITED STATES, October 15, 2020 /⁨EINPresswire.com⁩/ -- UbiVac Inc. is pleased to …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on September 24, 2020 - 19:17 GMT

Triplet Immunotherapy for Metastatic Triple Negative Breast Cancer Presented at Chinese Society for Clinical Oncology

UbiVac CEO discusses how biomarker data and preclinical studies led to a first-in-human Immunotherapy being tested in patients with metastatic breast cancer XIAMEN, CHINA, September 24, 2020 /⁨EINPresswire.com⁩/ -- UbiVac, www.ubivac.com, a private, …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

The Newsroom of UbiVac